The U.S. Food and Drug Administration (FDA) has approved Medtronic’s Asleep Deep Brain Stimulation (DBS) surgery for people with Parkinson’s disease or essential tremor. “This is a significant advancement in our surgical offering, providing another safe and effective option for patients considering DBS,” Amaza Reitmeier, a vice…
News
The U.S. Food and Drug Administration (FDA) has agreed on the design of the upcoming Phase 2 SUNRISE-PD clinical trial to test BioVie’s oral candidate bezisterim as a first-line, stand-alone treatment for newly diagnosed Parkinson’s disease patients. Upon a protocol review, the agency recommended including assessments of motor…
The Parkinson’s Foundation has awarded more than $1 million in 92 community-based grants across 40 states in the U.S. to improve the quality of life of people with Parkinson’s disease. This year’s funding, which ranges between $10,000 to $25,000 per organization, was awarded to programs that address local Parkinson’s…
A protein called STAT3 protected nerve cells from degeneration and improved behavioral and motor outcomes in a rat model of Parkinson’s disease, a study reveals. STAT3 potentially offers “a new avenue for treatment against Parkinson’s,” researchers wrote in the study “STAT3 protects dopaminergic neurons against…
A study reports that the proteins NAP1 and SINTBAD play a role in regulating mitophagy, a process wherein damaged mitochondria are removed from cells, which is essential for helping them stay healthy. Mitophagy is impaired in Parkinson’s disease. “Targeting these proteins in [nerve cells] could be a potential avenue…
Note: This article was updated Aug. 9, 2024, to correct that the improvement seen in good on time in additional analyses was 1.5 hours per dose. The U.S. Food and Drug Administration (FDA) has approved IPX203, a novel extended-release formulation of levodopa and carbidopa, for Parkinson’s disease.
A new visual diagnostic technique called Cap-QuIC has the potential to advance the early detection of neurodegenerative diseases, such as Parkinson’s disease. “The simplicity and efficiency of Cap-QuIC could lower the barriers to routine screening for neurodegenerative diseases, ultimately leading to earlier intervention and better patient outcomes,” Hye Yoon…
Researchers have developed a new mouse model that affects nerve cells in the eye that could help in studying disease mechanisms and treatment approaches in Parkinson’s disease. The mice are lacking the protein VPS35 in specific cells of the eye and developed protein deposits that contain alpha-synuclein, neurodegeneration, and…
Compounds called polyphenols in the Ecklonia cava seaweed eased motor and nonmotor symptoms in a mouse model of Parkinson’s disease, a study reports. Treatment with the polyphenols, which are natural antioxidants and anti-inflammatory agents, also prevented the loss of dopamine-producing neurons, a hallmark of Parkinson’s disease. The benefits are…
From Monterey Bay in California to Hanalei Bay in Kauai, Hawaii, Team HPP (Human Powered Potential) has rowed 2,800 miles across the Pacific Ocean and raised $28 million to benefit The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and its efforts to better treat and cure Parkinson’s disease.
Recent Posts
- Large study: Quitting smoking linked to increased risk of Parkinson’s
- A vocabulary lesson Parkinson’s families will intimately understand
- States push to ban or restrict paraquat, a herbicide linked to Parkinson’s
- My experiences with the stages of grief since my Parkinson’s diagnosis
- How a simple plant protein could help clear Parkinson’s toxins